MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

AbbVie Inc

Avatud

SektorTervishoid

183.14 2.19

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

178.98

Max

186.19

Põhinäitajad

By Trading Economics

Sissetulek

-1.6B

-23M

Müük

642M

15B

P/E

Sektori keskmine

71.496

57.333

Aktsiakasum

2.16

Dividenditootlus

3.86

Kasumimarginaal

-0.152

Töötajad

55,000

EBITDA

-4.4B

535M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+17.54% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

3.86%

2.63%

Järgmine tulemuste avaldamine

25. apr 2025

Järgmine dividendimakse kuupäev

15. mai 2025

Järgmine aktsia dividendi kuupäev (ex-date)

14. juuli 2025

Turustatistika

By TradingEconomics

Turukapital

-29B

306B

Eelmine avamishind

180.95

Eelmine sulgemishind

183.14

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

AbbVie Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. apr 2025, 18:18 UTC

Suurimad hinnamuutused turgudel

Pharma Shares Reverse Losses After Tariff Pause

9. apr 2025, 09:39 UTC

Suurimad hinnamuutused turgudel

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

27. veebr 2025, 22:48 UTC

Omandamised, ülevõtmised, äriostud

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12. veebr 2025, 13:41 UTC

Suurimad hinnamuutused turgudel

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31. jaan 2025, 13:28 UTC

Tulu

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14. märts 2025, 09:30 UTC

Peamised uudised

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3. märts 2025, 15:04 UTC

Omandamised, ülevõtmised, äriostud

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28. veebr 2025, 12:00 UTC

Peamised uudised

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6. veebr 2025, 13:25 UTC

Peamised uudised
Tulu

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6. veebr 2025, 12:00 UTC

Tulu

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5. veebr 2025, 12:00 UTC

Peamised uudised

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31. jaan 2025, 15:50 UTC

Peamised uudised
Tulu

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. jaan 2025, 13:51 UTC

Tulu

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31. jaan 2025, 13:47 UTC

Peamised uudised
Tulu

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31. jaan 2025, 13:24 UTC

Market Talk
Tulu

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31. jaan 2025, 12:46 UTC

Tulu

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31. jaan 2025, 12:39 UTC

Tulu

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31. jaan 2025, 12:38 UTC

Tulu

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31. jaan 2025, 12:38 UTC

Tulu

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31. jaan 2025, 12:37 UTC

Tulu

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31. jaan 2025, 12:37 UTC

Tulu

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Loss $22M >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Adj EPS $2.16 >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31. jaan 2025, 12:36 UTC

Tulu

AbbVie 4Q Loss/Shr 2c >ABBV

Võrdlus sarnastega

Hinnamuutus

AbbVie Inc Prognoos

Hinnasiht

By TipRanks

17.54% tõus

12 kuu keskmine prognoos

Keskmine 212 USD  17.54%

Kõrge 241 USD

Madal 190 USD

Põhineb 18 Wall Streeti analüütiku instrumendi AbbVie Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

18 ratings

13

Osta

5

Hoia

0

Müü

Tehniline skoor

By Trading Central

174.2 / 180.5Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bearish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.